

07 November 2006

[REDACTED]
Policy Officer
Cancerbackup
3 Bath Place
Rivington Street
London
EC2A 3JR

Sent via email

Dear [REDACTED]

Final Appraisal Determination: Bevacizumab and Cetuximab for Metastatic Colorectal Cancer

Thank you for your letter of 3 November addressed to [REDACTED]. [REDACTED] has retired from her duties at the Institute and I have taken over as Appeals Committee Chair.

In her letter to [REDACTED] of 5 October, [REDACTED] indicated that her initial view was that none of your appeal points was arguable under Ground 2 or under either of the two other grounds of appeal. She invited you to submit any further comments by 26 October before reaching her final decision. That deadline was subsequently extended to 3 November.

I note that in light of [REDACTED] comments, you have decided not to pursue your appeal in respect of bevacizumab.

You ask, however, that your appeal in respect of cetuximab should proceed on the basis that there has been some misinterpretation in the Final Appraisal Determination (FAD) regarding the drug and its use in treating patients with metastatic colorectal cancer (mCRC). Your argument is that cetuximab is a third line treatment for mCRC and not a "second line and subsequent treatment" as stated in the FAD and that the Institute has therefore prepared guidance which is perverse in the light of the evidence submitted,

The further elaboration which you have provided has persuaded me that your appeal in respect of cetuximab is arguably within Ground 2 of the permitted grounds of appeal and that it should be heard accordingly on 27 November.

Yours sincerely

[REDACTED]
Appeals Committee Chair

CC Bowel Cancer UK